Posted by Michael Wonder on 06 May 2025
Health Canada has granted approval for Tzield, the first and only disease-modifying therapy in auto-immune type 1 diabetes in Canada
5 May 2025 - Tzield is demonstrated to delay by a median of 2 years the onset of Stage 3 type 1 diabetes in patients 8 years of age and older currently with Stage 2.
Health Canada has issued a Notice of Compliance for Tzield (teplizumab), a first-in-class disease-modifying therapy for autoimmune type 1 diabetes, that delays the onset of Stage 3 type 1 diabetes in adult and paediatric patients 8 years of age and older currently living with Stage 2 type 1 diabetes.
